UBC talked with Josh Hardman, founder of Psychedelic Alpha, to discuss the evolving landscape of psychedelic drug development—from shifting regulatory expectations to the role of psychotherapy and the impact of stigma on patient access. Hardman shares a clear-eyed perspective on where the field stands today, the scientific rigor needed to advance it, and what he’s watching most closely as the industry moves toward potential first approvals.
Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.
Lorem ipsum dolor sit amet consectetur. Cras aliquam erat eget magna sollicitudin.
Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.
President & Chief Executive Officer
Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.
With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.
